Pulmobiotics SL

More than 1 billion persons suffer from chronic respiratory conditions worldwide, including 235 million people suffering from asthma and more than 200 million people enduring chronic obstructive pulmonary disease (COPD) which is moderate to severe in 65 million. 8.7 million people develop tuberculosis annually and more than 50 million people struggle with occupational lung diseases. Respiratory diseases are also among the leading causes of death worldwide, with 3.5 million deaths being attributed to lower respiratory diseases, 3.3 million to COPD and 1.4 million to tracheal, bronchial or lung cancer.

Building on over 10 years of research funded with over 14m € by Spanish and EU grant agencies (details here), we have developed a proprietary microbial engineering and synthetic biology toolbox that underpins a novel live biotherapeutics platform. Pulmobiotics will use its technology to discover and develop novel treatments and vaccines for respiratory diseases, which are among the most common causes of severe illness and death worldwide.